Blood cancers occur when abnormal blood cells are out of control and interrupt the normal blood cells. Most blood cancers start in the bone marrow, the place where blood is produced. Some common blood cancer treatments include:
—Stem cell transplantation
One particular type of blood cancer called multiple myeloma, however, is resistant to the standard therapies above. But don't worry, researches have already found a new therapy that can treat this blood cancer.
The new type of therapy
According to the results of a clinical trial published in The New England Journal of Medicine, a combination of selinexor with dexamethasone significantly knocked down the cancer in more than 25 % of patients and caused at least a minimal response in almost 40 % of patients.
In this study, 122 patients were asked to take selinexor and dexamethasone, both oral drugs, in trials across the United States and Europe.
Selinexor has already been approved by the FDA for patients who are resistant to other therapies in early July. And selinexor is also being investigated if it can treat multiple myeloma in combination with other approved drugs.
A major milestone in multiple myeloma
"This study proved that a novel, first-in-class drug with a new mechanism of action can kill a patient's cancer cells," said the study's senior author, Sundar Jagannath. "This proved that the drug worked in patients who had exhausted every other treatment and who would have been placed on hospice care otherwise."
"An increasing number of patients have resistance to the standard drugs used in the treatment of multiple myeloma, and the overall survival in these patients is short, sometimes less than three months," said the study's first author Ajai Chari.
Therefore, this study shows a bright future for patients with multiple myeloma who cannot be treated by other traditional therapies effectively.